None
EN
Biogen to acquire Alcyone Therapeutics for $85m
NULL
Pharmaceutical Business review
ThecaFlex DRx is an investigational implantable device to deliver antisense oligonucleotides (ASOs) intrathecally. The device administers medicines to patients with neurologic disorders. It is designed to offer an
The post Biogen to acquire Alcyone Therapeutics for $85m appeared first on Pharmaceutical Business review.